Pharma Stocks To Buy 2017 (360p | 720p)

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec

: Maintained its lead in prescription sales and remained a "Strong Buy" due to its robust clinical pipeline and steady dividend. pharma stocks to buy 2017

The year’s biggest winners were often clinical-stage companies that secured major regulatory wins or licensing deals. While 2017 was a banner year, several headwinds

: Led the industry in R&D spending, focused heavily on its blockbuster immunotherapy Keytruda . : A top pick for dividends (yielding ~4

: A top pick for dividends (yielding ~4.2%) and growth, with shares rising 45% in 2017 driven by Humira and its cancer drug pipeline.

: Held its position as the world's largest pharma company by market cap ($387B in 2017). ⚠️ Key Trends & Risks

For investors seeking stability and income, large-cap pharma stocks remained dominant through R&D investment and consistent payouts.